• BIVDA members area

Members' Press Releases

SpeeDx receives FDA clearance for Mycoplasma genitalium product

SYDNEY, AUSTRALIA – (April 19, 2018). SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company’s recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company – SpeeDx Pty Ltd – as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the ResistancePlus MG assay.*

Read the rest of entry »

Novodiag® Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens

Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.

Read the rest of entry »

MBM and OCB launch ColoProg in China on March 7th 2018

Oxford developed prognostic assay for risk of post-surgical recurrence in
Stage II colorectal cancer patients to be available throughout China

Read the rest of entry »

Study confirms HORIBA POCT analyser enables earlier clinical decision-making in emergency paediatrics

Northampton, UK – 20th March 2018 – HORIBA UK Ltd, Medical announces that in a study recently undertaken and published as a case study by the Oxford Academic Health Science Network (AHSN), its Microsemi CRP point-of-care (POC) analyser was found to enable more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units. The study [1] found that using POCT as a replacement for laboratory tests resulted in earlier decision-making in approximately 75% of cases across three hospital sites. Economic analysis across these sites found that this could result in net annual cost savings due to reduced staff time, as well as faster decisions on antibiotic use.

Read the rest of entry »

OGT enhances customer experience with new Cytocell website

Oxford, UK – 7 March 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched a new version of its Cytocell® fluorescence in situ hybridisation (FISH) probes website - designed to provide a wealth of information and advice, offer refined functionality, and be easy-to-use. Cytocell is well known for its complete and comprehensive range of FISH probes, exceptional customer support, service and expertise. In the spirit of sharing this expertise and knowledge, OGT has redeveloped the website to increase accessibility to the brand’s know-how.

Read the rest of entry »

Cytox awarded new Innovate UK funding for Alzheimer’s disease testing

8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, is pleased to announce that, in partnership with Cardiff University, the company has been awarded funding by Innovate UK. The award is £800,000 ($1.3m) out of a total project value of £1m ($1.6m) over two years.

Read the rest of entry »

RPS Diagnostics partners with Atomo Diagnostics to develop next generation Febridx blood tests for Antibiotic Stewardship in the Outpatient setting

 

Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, RPS Diagnostics (RPS®), and Australian medical device company, Atomo Diagnostics, announced today that they have entered into a commercial and development partnership to create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at the point-of-care.

Read the rest of entry »

Radiometer helps enhance patient outcomes at the University of Leicester Hospitals NHS Trust

Crawley, UK – 15 February 2018 – Radiometer Ltd has implemented its AQURE Enterprise point-of-care (POC) data management system at the University of Leicester Hospitals NHS Trust’s new Emergency Department. Radiometer Ltd has also supported them in configuring the interface of the Trust’s Sunquest Integrated Clinical Environment (ICE) EPR system so that blood gas test results are automatically linked to an individual’s electronic patient record (EPR). Blood gas tests are ordered via the ICE-EPR system and processed within the Emergency Department on Radiometer’s ABL90 FLEX PLUS blood gas analysers, with results being delivered to the clinician via Sunquest ICE in as little as 1 min. The almost immediate display of accurate results can have a significant effect on patient outcomes.

Read the rest of entry »

A Valuable New Information Resource for Faecal Immunochemical Testing (FIT) for Bowel Cancer Detection

www.faecal-immunochemical-test.co.uk is a dedicated new website, developed by Alpha Laboratories Ltd., to raise awareness amongst clinicians, laboratories, patients and the public, about advances in the detection of colorectal cancer using the faecal immunochemical test (FIT). You can find out all about why FIT is being adopted by the bowel cancer screening programmes and is also now recommended by NICE DG30, to guide referral for colorectal cancer in primary care for symptomatic patients.

Read the rest of entry »

Expanding Global IVD Business Exhibits at the World’s Largest Lab Expo

BBI Solutions (BBI), a leading and rapidly expanding manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, is gearing up to attend MEDLAB Middle East in Dubai next month.

Read the rest of entry »

Pages: Previous1234567...32NextReturn Top

Archive